Novartis Pluvicto™ shows clinically meaningful and highly ...

October 23, 2023

The Phase III PSMAfore trial demonstrated Pluvicto™ significantly improved radiographic progression-free survival (rPFS) in PSMA-positive mCRPC patients, doubling median rPFS to 12.0 months. Pluvicto also enhanced quality of life and showed favorable safety. OS data collection continues, with next analysis expected in 2024.

Related Clinical Trials

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Reference News

novartis.com

Novartis Pluvicto™ shows clinically meaningful and highly ...